Beyond Air, Inc. (XAIR) Stock Analysis and Metrics

Beyond Air

NASDAQ: XAIR

$5.20 ▼ -0.23 (-4.24%)

At close: Jul 24, 2026 · 3:50 PM UTC

Financial Ratios

Market Cap2.25 Mn

P/E-0.07

P/S0.29

Div. Yield0.00

Total Debt (Qtr)802,000.00

Revenue Growth (1y) (Qtr)65.54

Add ratio to table…

About

Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company that develops a nitric oxide generation and delivery platform called LungFit® capable of producing nitric oxide from ambient air. The LungFit® system can generate nitric oxide concentrations ranging from 0.5 parts per million to 400 parts per million and deliver it continuously or for a fixed amount of time at various flow rates with the ability to titrate dose on demand or maintain a constant dose. The company’s first product, LungFit® PH, received FDA premarket approval in June 2022 for the treatment of persistent pulmonary hypertension of the newborn and later obtained European CE mark approval in November 2024 for additional indications in neonates, infants, children and adults undergoing heart surgery. Beyond Air also advances pipeline candidates LungFit® PRO for viral lung infections and LungFit® GO for nontuberculous mycobacterial lung disease, while exploring nitric oxide based therapies for solid tumors through its majority owned affiliate Beyond Cancer and neuronal nitric oxide synthase inhibitors for autism spectrum disorder through its affiliate NeuroNOS.

Revenue is generated primarily from the sale of LungFit® PH devices and associated disposables to hospitals and other healthcare providers. The company began marketing LungFit® PH in the United States in September 2022 and has secured distribution agreements covering France, Italy, Turkey, India, Saudi Arabia, Morocco and other regions, anticipating meaningful contribution to revenue starting in fiscal 2026. Based on internal estimates, the US sales potential for LungFit® PH in persistent pulmonary hypertension of the newborn is approximately $350 million and the worldwide sales potential is approximately $700 million or greater. Future revenue streams are expected from the commercialization of LungFit® PRO for viral lung infections, with an estimated US market potential greater than $1.5 billion and worldwide market potential greater than $3 billion, and LungFit® GO for nontuberculous mycobacterial lung disease, with an estimated US market potential greater than $1 billion and worldwide market potential greater than $2.5 billion. Additionally, the company expects to receive royalties and milestone payments from its oncology and neurology subsidiaries and pays a low single digit royalty to NitricGen under the licensed eNOGenerator technology. Manufacturing is outsourced to contract manufacturers Spartronics LLC and Medisize Ireland Limited with finished goods staged from a central warehouse in Atlanta, Georgia.

Beyond Air competes in the nitric oxide therapy market against established players such as Mallinckrodt’s INOMAX®, Linde Group’s NOxBOX®, Air Liquide’s KINOX™, VERO Biotech’s GENOSYL DS and Bellerophon Therapeutics, which are developing NO delivery systems for various respiratory and cardiac indications. The company’s competitive advantage stems from its ability to generate nitric oxide directly from ambient air, eliminating the need for high pressure cylinders and complex purging procedures, which reduces logistical burden on hospital staff. LungFit® systems can deliver nitric oxide concentrations above 150 parts per million, enabling potential antimicrobial applications beyond vasodilation, and include an integrated monitoring system that continuously measures nitric oxide, nitrogen dioxide and inspired oxygen fractions. The device is portable and can be administered non invasive through a facial mask, making it suitable for use in intensive care units, operating rooms and outpatient settings. Beyond Air’s intellectual property portfolio includes a global exclusive license to the eNOGenerator from NitricGen and numerous issued patents and pending applications covering its NO generation, delivery and monitoring technologies.

The company serves hospitals, neonatal intensive care units, pediatric cardiology wards, adult cardiac surgery centers and pulmonary clinics that treat patients with hypoxic respiratory failure, pulmonary hypertension or severe lung infections. While specific customer names are not disclosed in the filing, the target clientele includes major medical centers and community hospitals across the United States and international markets where LungFit® PH has received regulatory clearance, including Australia, New Zealand, Hong Kong, Thailand and countries in Europe, the Middle East and Asia served through distribution agreements with partners such as Getz Healthcare, and direct agreements covering France, Italy, Turkey, India, Saudi Arabia and Morocco. Beyond Air markets its products directly through a field sales team and provides necessary training via a separate team of clinical specialists.

Investment Thesis

▲ Bull case

Beyond Air's (XAIR) commercial execution is accelerating faster than market expectations, driven by the successful penetration of the VA Medical Center system via catalog access outside standard RFP processes, which provides a scalable blueprint for broader federal healthcare adoption. This early win, combined with national GPO agreements through Premier and Vizient covering nearly 3,000 U.S. hospitals, positions the company to leverage its installed base of over 45 hospitals with above 90% retention and multiyear agreements for over half of customers to drive rapid expansion. Management's focus on identifying high-propensity accounts through refined CRM rigor and demand generation is reducing sales cycle friction, and the international footprint now spans 40 countries with recent wins in key markets like Germany and Brazil, where reordering of accessories signals genuine clinical adoption and stickiness. These factors suggest revenue growth could exceed current estimates as the sales engine scales, particularly as Gen II readiness advances. The Gen II LungFit PH system represents a transformative catalyst that the market is underpricing, with management expressing high confidence in pre-year-end 2026 FDA approval based on constant, positive interactions and no perceived major hurdles. Critical durability testing has already surpassed 3,000 hours, confirming the ability to extend service intervals from 1,000 hours (Gen I) to at least 3,000 hours without additional FDA requirements—a key value proposition that reduces hospital operational costs and increases device uptime. This reliability advantage, combined with Gen II's reduced size, simplified operation, and air/ground transport compatibility, expands the addressable market beyond Gen I's non-transport focus and supports long-term gross margin expansion toward the 70% target. The de-risked regulatory path and tangible performance benefits create a clear inflection point for accelerated adoption post-approval. Strategic balance sheet actions have significantly derisked the near-term outlook while preserving upside potential. The $4.5 million equity financing post-quarter, combined with the $5 million January financing and access to a $32 million equity line of credit with Streeterville Capital, extends cash runway into calendar 2027. More importantly, the divestiture of NeuroNOS to XTL Biopharmaceuticals for a 19.9% stake, $1 million cash, and up to $31.5 million in milestones removes a non-core distraction while providing potential upside from XTL's advancement of the autism and glioblastoma pipeline. Management's statement that runway extends "potentially to profitability provided we continue to hit our current revenue estimates and continue to control costs" highlights a credible path to breakeven that is not fully reflected in the current valuation, especially as gross profit turned positive in Q3 FY26 at $300,000 versus a gross loss of $200,000 year-ago.

Beyond Air's (XAIR) commercial execution is accelerating faster than market expectations, driven by the successful penetration of the VA Medical Center system via catalog access outside standard RFP processes, which provides a scalable blueprint for broader federal healthcare adoption. This early win, combined with national GPO agreements through Premier and Vizient covering nearly 3,000 U.S. hospitals, positions the company to leverage its installed base of over 45 hospitals with above 90% retention and multiyear agreements for over half of customers to drive rapid expansion. Management's focus on identifying high-propensity accounts through refined CRM rigor and demand generation is reducing sales cycle friction, and the international footprint now spans 40 countries with recent wins in key markets like Germany and Brazil, where reordering of accessories signals genuine clinical adoption and stickiness. These factors suggest revenue growth could exceed current estimates as the sales engine scales, particularly as Gen II readiness advances. The Gen II LungFit PH system represents a transformative catalyst that the market is underpricing, with management expressing high confidence in pre-year-end 2026 FDA approval based on constant, positive interactions and no perceived major hurdles. Critical durability testing has already surpassed 3,000 hours, confirming the ability to extend service intervals from 1,000 hours (Gen I) to at least 3,000 hours without additional FDA requirements—a key value proposition that reduces hospital operational costs and increases device uptime. This reliability advantage, combined with Gen II's reduced size, simplified operation, and air/ground transport compatibility, expands the addressable market beyond Gen I's non-transport focus and supports long-term gross margin expansion toward the 70% target. The de-risked regulatory path and tangible performance benefits create a clear inflection point for accelerated adoption post-approval. Strategic balance sheet actions have significantly derisked the near-term outlook while preserving upside potential. The $4.5 million equity financing post-quarter, combined with the $5 million January financing and access to a $32 million equity line of credit with Streeterville Capital, extends cash runway into calendar 2027. More importantly, the divestiture of NeuroNOS to XTL Biopharmaceuticals for a 19.9% stake, $1 million cash, and up to $31.5 million in milestones removes a non-core distraction while providing potential upside from XTL's advancement of the autism and glioblastoma pipeline. Management's statement that runway extends "potentially to profitability provided we continue to hit our current revenue estimates and continue to control costs" highlights a credible path to breakeven that is not fully reflected in the current valuation, especially as gross profit turned positive in Q3 FY26 at $300,000 versus a gross loss of $200,000 year-ago.

▼ Bear case

Beyond Air's (XAIR) revenue growth, while impressive on a percentage basis, remains from an extremely low base of $2.2 million in Q3 FY26, and the company faces significant hurdles in scaling beyond early adopters despite GPO access. The sales cycle for hospital systems remains lengthy at 6–9 months on average, and management admitted it could be longer, with no evidence of meaningful acceleration in converting Premier/Vizient contract access into actual orders. International expansion, while broad in country count (40), shows limited depth, with recent wins in markets like Sri Lanka and the Netherlands unlikely to drive material near-term revenue, and reliance on distributor-led models in regions requiring tenders or national frameworks introduces execution risk and margin dilution. The VA Medical Center win, though symbolically important, was achieved through catalog access outside standard RFPs—a narrow pathway that may not replicate across the larger federal system, casting doubt on the scalability of this early success. The Gen II FDA approval timeline, while presented with confidence, carries substantial execution risk that the market may be underestimating, particularly given the company's history of delays and the remaining gating factor of contract manufacturer inspection readiness. Management acknowledged that work with the contract manufacturer must be completed before FDA inspection can occur, and any delays in this process—common in medical device scale-up—could push approval beyond the pre-year-end 2026 target. Furthermore, while durability testing has exceeded 3,000 hours, the claimed extension of service intervals to "at least 3,000 hours" remains unverified in real-world hospital settings, and pricing pressures or reimbursement challenges could prevent the realization of the 70% gross margin target, leaving Gen II's financial upside unproven and potentially inferior to expectations if hospitals resist premium pricing for incremental benefits. Financial sustainability remains a critical concern despite recent financing actions, as the company continues to burn cash at a significant rate, with net cash burn of $4.3 million in Q3 FY26 and operating expenses still high at $6.9 million. The path to profitability hinges entirely on hitting aggressive revenue estimates while maintaining strict cost control—a scenario that leaves little room for error, especially if Gen II launch delays force continued investment in both generations or if SG&A must increase to support commercial scaling. The $17.8 million cash position, bolstered by the post-quarter $4.5 million equity financing, provides runway into calendar 2027 only under optimistic assumptions, and any setback in revenue growth or unexpected costs could rapidly erode this buffer, forcing dilutive financing or strategic compromises well before profitability is achievable.

Beyond Air's (XAIR) revenue growth, while impressive on a percentage basis, remains from an extremely low base of $2.2 million in Q3 FY26, and the company faces significant hurdles in scaling beyond early adopters despite GPO access. The sales cycle for hospital systems remains lengthy at 6–9 months on average, and management admitted it could be longer, with no evidence of meaningful acceleration in converting Premier/Vizient contract access into actual orders. International expansion, while broad in country count (40), shows limited depth, with recent wins in markets like Sri Lanka and the Netherlands unlikely to drive material near-term revenue, and reliance on distributor-led models in regions requiring tenders or national frameworks introduces execution risk and margin dilution. The VA Medical Center win, though symbolically important, was achieved through catalog access outside standard RFPs—a narrow pathway that may not replicate across the larger federal system, casting doubt on the scalability of this early success. The Gen II FDA approval timeline, while presented with confidence, carries substantial execution risk that the market may be underestimating, particularly given the company's history of delays and the remaining gating factor of contract manufacturer inspection readiness. Management acknowledged that work with the contract manufacturer must be completed before FDA inspection can occur, and any delays in this process—common in medical device scale-up—could push approval beyond the pre-year-end 2026 target. Furthermore, while durability testing has exceeded 3,000 hours, the claimed extension of service intervals to "at least 3,000 hours" remains unverified in real-world hospital settings, and pricing pressures or reimbursement challenges could prevent the realization of the 70% gross margin target, leaving Gen II's financial upside unproven and potentially inferior to expectations if hospitals resist premium pricing for incremental benefits. Financial sustainability remains a critical concern despite recent financing actions, as the company continues to burn cash at a significant rate, with net cash burn of $4.3 million in Q3 FY26 and operating expenses still high at $6.9 million. The path to profitability hinges entirely on hitting aggressive revenue estimates while maintaining strict cost control—a scenario that leaves little room for error, especially if Gen II launch delays force continued investment in both generations or if SG&A must increase to support commercial scaling. The $17.8 million cash position, bolstered by the post-quarter $4.5 million equity financing, provides runway into calendar 2027 only under optimistic assumptions, and any setback in revenue growth or unexpected costs could rapidly erode this buffer, forcing dilutive financing or strategic compromises well before profitability is achievable.

Award Type Breakdown of Revenue (2026)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Award Type Breakdown of Revenue (2026)

Award Type Breakdown of Revenue (2026)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Award Type Breakdown of Revenue (2026)

Award Type Breakdown of Revenue (2026)

Peer Comparison

Create an account

Sign In

Reset Password